Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
RAPP
RAPP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest RAPP ETF News Today | Earnings, Events & Price Alerts
RAPP News
Rapport Therapeutics (RAPP) Receives FDA Clearance to Advance RAP-219 into Phase 3 Trials
Jan 08 2026
NASDAQ.COM
Cormorant Increases Stake in Rapport Therapeutics by 251,600 Shares Worth $94.82 Million
Dec 22 2025
Fool
Cormorant Increases Stake in Rapport Therapeutics by 251,600 Shares Worth $61.38 Million
Dec 22 2025
NASDAQ.COM
Rapport Therapeutics, Inc. (RAPP) Sees a 9.03% Increase Over the Past Week: Key Insights to Consider
Dec 08 2025
NASDAQ.COM
Valuation Assessment of Rapport Therapeutics (RAPP) Following 60% Increase in Share Price This Year
Dec 07 2025
Yahoo Finance
RAP-219 Phase 2a Seizure Results and Upcoming Pivotal Trials Could Influence Investment Decisions in Rapport Therapeutics (RAPP)
Dec 06 2025
Yahoo Finance
Rapport Therapeutics Reports RAP-219 Clinical Data, Significantly Reducing Seizure Frequency
Dec 05 2025
Globenewswire
Rapport Therapeutics Reports RAP-219 Clinical Data, Significantly Reducing Seizure Frequency
Dec 05 2025
Newsfilter
Extreme Networks Analyst Starts Coverage with Optimism; Check Out the Top 5 Initiations for Wednesday
Nov 19 2025
Benzinga
Biotech Makes a Comeback: Reasons to Add These Rising Stocks to Your Portfolio Today.
Nov 03 2025
MarketWatch
Biotech Stocks Surge in After-Hours Trading on Friday in Anticipation of Important Clinical Trial Announcements
Sep 22 2025
NASDAQ.COM
Rapport Therapeutics, Inc. (RAPP) Shares Insights at TD Cowen's 5th Annual Summit on Novel Mechanisms in Neuropsychiatry and Epilepsy
Sep 17 2025
Newsfilter
Insider Buying Update for Wednesday, September 17: LBRX and RAPP
Sep 17 2025
NASDAQ.COM
Truist Securities Begins Coverage of Rapport Therapeutics (RAPP) with a Buy Rating
Sep 17 2025
NASDAQ.COM
Truist Securities Begins Coverage of Rapport Therapeutics with a Buy Rating and Sets Price Target at $44
Sep 16 2025
Benzinga
Top Analysts Recommend 3 Stocks to Purchase Now, 9/16/2025
Sep 16 2025
TipRanks
Show More News
